Biliary stent therapy for dominant strictures in patients affected by primary sclerosing cholangitis

Pathobiology

Volumn 80, Issue 4, 2013, Pages 182-193

  Abu Wasel, Bassam ^a   Keough, Valerie ^a   Renfrew, Paul D ^a   Molinari, Michele ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Biliary stent therapy; Dominant strictures; Primary sclerosing cholangitis

Indexed keywords

CA 19-9 ANTIGEN; CONTRAST MEDIUM; POLITEF; POLYETHYLENE; POLYURETHAN; URSODEOXYCHOLIC ACID;

ARTICLE; BALLOON DILATATION; BILE DUCT DILATATION; BILE FLOW; BILIARY STENT; BILIARY TRACT ENDOSCOPY; CHOLANGIOGRAPHY; CHOLESTASIS; COMMON BILE DUCT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DOMINANT STRICTURE; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC THERAPY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HOSPITALIZATION; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; JAUNDICE; LIVER FUNCTION TEST; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; METAL STENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PLASTIC STENT; PREDICTIVE VALUE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; SELF EXPANDING STENT; WEIGHT REDUCTION; BILE DUCT; BILIARY TRACT SURGERY; CHOLANGITIS, SCLEROSING; COMPLICATION; CONSTRICTION, PATHOLOGIC; DILATATION; PALLIATIVE THERAPY; PATHOLOGY; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; STENT; TREATMENT OUTCOME;

BILE DUCTS; BILIARY TRACT SURGICAL PROCEDURES; CHOLANGITIS, SCLEROSING; CONSTRICTION, PATHOLOGIC; DILATATION; HUMANS; PALLIATIVE CARE; SENSITIVITY AND SPECIFICITY; STENTS; TREATMENT OUTCOME;

EID: 84877880193     PISSN: 10152008     EISSN: 14230291     Source Type: Journal    
DOI: 10.1159/000347057     Document Type: Article

References (94)

1. Lee YM, Kaplan MM: Primary sclerosing cholangitis. N Engl J Med 1995; 332:924-933.
2. Nakanuma Y, Hirai N, Kono N, Ohta G: His-tological and ultrastructural examination of the intrahepatic biliary tree in primary scle-rosing cholangitis. Liver 1986; 6:317-325.
3. Broome U, Grunewald J, Scheynius A, et al: Preferential V beta3 usage by hepatic T lymphocytes in patients with primary sclerosing cholangitis. J Hepatol 1997; 26:527-534.
4. Bambha K, Kim WR, Talwalkar J, et al: Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125:1364-1369.
5. Boberg KM, Aadland E, Jahnsen J, et al: Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol 1998; 33:99-103.
6. Kingham JG, Kochar N, Gravenor MB: Incidence, clinical patterns, and outcomes of primary sclerosing cholangitis in South Wales, United Kingdom. Gastroenterology 2004; 126:1929-1930.
7. Smith T, Befeler AS: High-dose ursodeoxy-cholic acid for the treatment of primary scle-rosing cholangitis. Curr Gastroenterol Rep 2007; 9:54-59.
8. Charatcharoenwitthaya P, Lindor KD: Primary sclerosing cholangitis: diagnosis and management. Curr Gastroenterol Rep 2006; 8:75-82.
9. Fickert P, Wagner M, Marschall HU, et al: 24-norUrsodeoxycholic acid is superior to ur-sodeoxycholic acid in the treatment of scle-rosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006; 130:465-481.
10. Beuers U, Spengler U, Kruis W, et al: Ursode-oxycholic acid for treatment of primary scle-rosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16:707-714.
11. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Chol-angitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336:691-695.
12. van Hoogstraten HJ, Vleggaar FP, Boland GJ, et al: Budesonide or prednisone in combination with ursodeoxycholic acid in primary scle-rosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000; 95:2015-2022.
13. Vacca M, Krawczyk M, Petruzzelli M, et al: Current treatments of primary sclerosing cholangitis. Curr Med Chem 2007; 14:2081-2094.
14. Ishibashi H, Komori A, Shimoda S, Gershwin ME: Guidelines for therapy of autoimmune liver disease. Semin Liver Dis 2007; 27:214-226.
15. Stiehl A: Primary sclerosing cholangitis: the role of endoscopic therapy. Semin Liver Dis 2006; 26:62-68.
16. Stiehl A, Rost D: Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis. Clin Rev Allergy Immunol 2005; 28:159-165.
17. Yamamoto T, Hirohashi K, Kubo S, et al: Surgery for segmental primary sclerosing cholan-gitis. Hepatogastroenterology 2004; 51:668-671.
18. Hirai I, Ishiyama S, Fuse A, et al: Primary scle-rosing cholangitis successfully treated by resection of the confluence of the hepatic duct. J Hepatobiliary Pancreat Surg 2001; 8:169-173.
19. Ahrendt SA, Pitt HA, Kalloo AN, et al: Primary sclerosing cholangitis: resect, dilate, or transplant? Ann Surg 1998; 227:412-423.
20. Van Laethem JL, Deviere J, Bourgeois N, et al: Cholangiographic findings in deteriorating primary sclerosing cholangitis. Endoscopy 1995; 27:223-228.
21. Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R: Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:502-508.
22. Gossard AA, Angulo P, Lindor KD: Secondary sclerosing cholangitis: a comparison to primary sclerosing cholangitis. Am J Gastro-enterol 2005; 100:1330-1333.
23. Olsson R, Boberg KM, de Muckadell OS, et al: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterol-ogy 2005; 129:1464-1472.
24. LaRusso NF, Shneider BL, Black D, et al: Primary sclerosing cholangitis: summary of a workshop. Hepatology 2006; 44:746-764.
25. Ponsioen CY, Lam K, van Milligen de Wit AW, et al: Four years' experience with short-term stenting in primary sclerosing cholangi-tis. Am J Gastroenterol 1999; 94:2403-2407.
26. Stiehl A, Rudolph G, Kloters-Plachky P, et al: Development of dominant bile duct stenoses in patients with primary sclerosing cholangi-tis treated with ursodeoxycholic acid: outcome after endoscopic treatment. J Hepatol 2002; 36:151-156.
27. van Milligen de Wit AW, van Bracht J, Rauws EA, et al: Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. Gastrointest En-dosc 1996; 44:293-299.
28. Olsson RG, Asztely MS: Prognostic value of cholangiography in primary sclerosing chol-angitis. Eur J Gastroenterol Hepatol 1995; 7: 251-254.
29. MacCarty RL, LaRusso NF, Wiesner RH, Ludwig J: Primary sclerosing cholangitis: findings on cholangiography and pancreatog-raphy. Radiology 1983; 149:39-44.
30. May GR, Bender CE, LaRusso NF, Wiesner RH: Nonoperative dilatation of dominant strictures in primary sclerosing cholangitis. AJR Am J Roentgenol 1985; 145:1061-1064.
31. Tischendorf JJ, Kruger M, Trautwein C, et al: Cholangioscopic characterization of dominant bile duct stenoses in patients with primary sclerosing cholangitis. Endoscopy 2006; 38:665-669.
32. Bergquist A, Broome U: Hepatobiliary and extra-hepatic malignancies in primary scle-rosing cholangitis. Best Pract Res Clin Gastro-enterol 2001; 15:643-656.
33. Farrant JM, Hayllar KM, Wilkinson ML, et al: Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenter-ology 1991; 100:1710-1717.
34. Kaya M, de Groen PC, Angulo P, et al: Treatment of cholangiocarcinoma complicating primary sclerosing cholangitis: the Mayo Clinic experience. Am J Gastroenterol 2001; 96:1164-1169.
35. Rosen CB, Nagorney DM, Wiesner RH, et al: Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991; 213: 21-25.
36. Pohl J, Ring A, Stremmel W, Stiehl A: The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. Eur J Gastroenterol Hepatol 2006; 18:69-74.
37. Lee JG, Schutz SM, England RE, et al: Endo-scopic therapy of sclerosing cholangitis. Hep-atology 1995; 21:661-667.
38. Bjornsson E, Boberg KM, Cullen S, et al: Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut 2002; 51:731-735.
39. Macchi V, Floreani A, Marchesi P, et al: Imaging of primary sclerosing cholangitis: preliminary results by two new non-invasive techniques. Dig Liver Dis 2004; 36:614-621.
40. Schulte SJ, Baron RL, Teefey SA, et al: CT of the extrahepatic bile ducts: wall thickness and contrast enhancement in normal and abnormal ducts. AJR Am J Roentgenol 1990; 154: 79-85.
41. Eracleous E, Genagritis M, Papanikolaou N, et al: Complementary role of helical CT chol-angiography to MR cholangiography in the evaluation of biliary function and kinetics. Eur Radiol 2005; 15:2130-2139.
42. Silverman W: Complication rate of endo-scopic retrograde cholangiopancreatography (ERCP) in patients with primary sclerosing cholangitis (PSC): is it safe? Gastroenterology 1994; 106:A359.
43. Moff SL, Kamel IR, Eustace J, et al: Diagnosis of primary sclerosing cholangitis: a blinded comparative study using magnetic resonance cholangiography and endoscopic retrograde cholangiography. Gastrointest Endosc 2006; 64:219-223.
44. van den Hazel SJ, Wolfhagen EH, van Buuren HR, et al: Prospective risk assessment of endo-scopic retrograde cholangiography in patients with primary sclerosing cholangitis. Dutch PSC Study Group. Endoscopy 2000; 32: 779-782.
45. Harbin WP, Mueller PR, Ferrucci JT Jr: Transhepatic cholangiography: complications and use patterns of the fine-needle technique: a multi-institutional survey. Radiology 1980; 135:15-22.
46. Cohen SA, Siegel JH, Kasmin FE: Complications of diagnostic and therapeutic ERCP. Abdom Imaging 1996; 21:385-394.
47. Berstad AE, Aabakken L, Smith HJ, et al: Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastro-enterol Hepatol 2006; 4:514-520.
48. Ponsioen CY, Vrouenraets SM, van Milligen de Wit AW, et al: Value of brush cytology for dominant strictures in primary sclerosing cholangitis. Endoscopy 1999; 31:305-309.
49. Boberg KM, Jebsen P, Clausen OP, et al: Diagnostic benefit of biliary brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol 2006; 45:568-574.
50. Ahrendt SA, Pitt HA, Nakeeb A, et al: Diagnosis and management of cholangiocarcino-ma in primary sclerosing cholangitis. J Gas-trointest Surg 1999; 3:357-367.
51. Vera A, Moledina S, Gunson B, et al: Risk factors for recurrence of primary sclerosing cholangitis of liver allograft. Lancet 2002; 360: 1943-1944.
52. Sebo TJ: Digital image analysis. Mayo Clin Proc 1995; 70:81-82.
53. Persons DL, Takai K, Gibney DJ, et al: Comparison of fluorescence in situ hybridization with flow cytometry and static image analysis in ploidy analysis of paraffin-embedded prostate adenocarcinoma. Hum Pathol 1994; 25: 678-683.
54. Moreno Luna LE, Kipp B, Halling KC, et al: Advanced cytologic techniques for the detection of malignant pancreatobiliary strictures. Gastroenterology 2006; 131:1064-1072.
55. Graziadei IW, Wiesner RH, Marotta PJ, et al: Long-term results of patients undergoing liver transplantation for primary sclerosing cholangitis. Hepatology 1999; 30:1121-1127.
56. Dickson ER, Murtaugh PA, Wiesner RH, et al: Primary sclerosing cholangitis: refinement and validation of survival models. Gastroen-terology 1992; 103:1893-1901.
57. Baluyut AR, Sherman S, Lehman GA, et al: Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangi-tis. Gastrointest Endosc 2001; 53:308-312.
58. Gotthardt DN, Rudolph G, Kloters-Plachky P, et al: Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment. Gastrointest Endosc 2010; 71:527-534.
59. Kaya M, Petersen BT, Angulo P, et al: Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. Am J Gastroenterol 2001; 96:1059-1066.
60. Angulo P, Lindor KD: Primary sclerosing cholangitis: emerging new promising therapies. J Clin Gastroenterol 2000; 31:271-273.
61. Raijman I: Biliary and pancreatic stents. Gas-trointest Endosc Clin N Am 2003; 13:561-592.
62. Khashab MA, Kim K, Hutfless S, et al: Predictors of early stent occlusion among plastic biliary stents. Dig Dis Sci 2012; 57:2446-2450.
63. van Berkel AM, van Marle J, van Veen H, et al: A scanning electron microscopic study of biliary stent materials. Gastrointest Endosc 2000; 51:19-22.
64. Costamagna G, Mutignani M, Rotondano G, et al: Hydrophilic hydromer-coated polyure-thane stents versus uncoated stents in malignant biliary obstruction: a randomized trial. Gastrointest Endosc 2000; 51:8-11.
65. Nakamura S, Ohara H, Yamada T, et al: Efficacy of plastic tube stents without side holes for middle and lower biliary strictures. J Clin Gastroenterol 2002; 34:77-80.
66. Costamagna G, Pandolfi M, Mutignani M, et al: Long-term results of endoscopic management of postoperative bile duct strictures with increasing numbers of stents. Gastrointest Endosc 2001; 54:162-168.
67. Draganov P, Hoffman B, Marsh W, et al: Long-term outcome in patients with benign biliary strictures treated endoscopically with multiple stents. Gastrointest Endosc 2002; 55: 680-686.
68. Perri V, Familiari P, Tringali A, et al: Plastic biliary stents for benign biliary diseases. Gas-trointest Endosc Clin N Am 2011; 21:405-433.
69. Pausawasadi N, Soontornmanokul T, Rerknimitr R: Role of fully covered self-expandable metal stent for treatment of benign biliary strictures and bile leaks. Korean J Ra-diol 2012; 13(suppl 1):S67-S73.
70. Srinivasan I, Kahaleh M: Biliary stents in the millennium. Adv Ther 2011; 28:960-972.
71. Cantu P, Hookey LC, Morales A, et al: The treatment of patients with symptomatic common bile duct stenosis secondary to chronic pancreatitis using partially covered metal stents: a pilot study. Endoscopy 2005; 37:735-739.
72. Foerster EC, Hoepffner N, Domschke W: Bridging of benign choledochal stenoses by endoscopic retrograde implantation of mesh stents. Endoscopy 1991; 23:133-135.
73. O'Brien SM, Hatfield AR, Craig PI, Williams SP: A 5-year follow-up of self-expanding metal stents in the endoscopic management of patients with benign bile duct strictures. Eur J Gastroenterol Hepatol 1998; 10:141-145.
74. Dumonceau JM, Nicaise N, Deviere J: The ul-traflex diamond stent for benign biliary obstruction. Gastrointest Endosc Clin N Am 1999; 9:541-545.
75. Kahaleh M, Tokar J, Le T, Yeaton P: Removal of self-expandable metallic Wallstents. Gas-trointest Endosc 2004; 60:640-644.
76. Shin HP, Kim MH, Jung SW, et al: Endoscop-ic removal of biliary self-expandable metallic stents: a prospective study. Endoscopy 2006; 38:1250-1255.
77. Kahaleh M, Behm B, Clarke BW, et al: Temporary placement of covered self-expandable metal stents in benign biliary strictures: a new paradigm? (with video). Gastrointest Endosc 2008; 67:446-454.
78. Mahajan A, Ho H, Sauer B, et al: Temporary placement of fully covered self-expandable metal stents in benign biliary strictures: midterm evaluation (with video). Gastrointest Endosc 2009; 70:303-309.
79. Sauer BG, Regan KA, Srinivasan I, Shami VM, Rehan ME, Ellen K: Temporary placement of covered self-expandable metal stents (CSEMS) in benign biliary strictures (BBS): eight years of experience. Gastrointest Endosc 2010; 71:110-111.
80. Cote GA, Kumar N, Ansstas M, et al: Risk of post-ERCP pancreatitis with placement of self-expandable metallic stents. Gastrointest Endosc 2010; 72:748-754.
81. Ho H, Mahajan A, Gosain S, et al: Management of complications associated with partially covered biliary metal stents. Dig Dis Sci 2010; 55:516-522.
82. Bezzi M, Zolovkins A, Cantisani V, et al: New ePTFE/FEP-covered stent in the palliative treatment of malignant biliary obstruction. J Vasc Interv Radiol 2002; 13:581-589.
83. Hausegger KA, Thurnher S, Bodendorfer G, et al: Treatment of malignant biliary obstruction with polyurethane-covered Wallstents. AJR Am J Roentgenol 1998; 170:403-408.
84. Park do H, Lee SS, Lee TH, et al: Anchoring flap versus flared end, fully covered self-expandable metal stents to prevent migration in patients with benign biliary strictures: a mul-ticenter, prospective, comparative pilot study (with videos). Gastrointest Endosc 2011; 73: 64-70.
85. Hwang JC, Kim JH, Yoo BM, et al: Temporary placement of a newly designed, fully covered, self-expandable metal stent for refractory bile leaks. Gut Liver 2011; 5:96-99.
86. Skolkin MD, Alspaugh JP, Casarella WJ, et al: Sclerosing cholangitis: palliation with percutaneous cholangioplasty. Radiology 1989; 170: 199-206
87. UNOS: http://www.unos.org (accessed February 29, 2008).
88. Ahrendt SA: Surgical approaches to strictures in primary sclerosing cholangitis. J Gastroin-test Surg 2008; 12:423-425.
89. Tsai S, Pawlik TM: Primary sclerosing chol-angitis: the role of extrahepatic biliary resection. Adv Surg 2009; 43:175-188.
90. van Boeckel PG, Vleggaar FP, Siersema PD: Plastic or metal stents for benign extrahepatic biliary strictures: a systematic review. BMC Gastroenterol 2009; 9:96.
91. Levy MJ, Baron TH, Clayton AC, et al: Prospective evaluation of advanced molecular markers and imaging techniques in patients with indeterminate bile duct strictures. Am J Gastroenterol 2008; 103:1263-1273.
92. Nakeeb A, Lipsett PA, Lillemoe KD, et al: Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma. Am J Surg 1996; 171:147-152.
93. Majoie CB, Smits NJ, Phoa SS, et al: Primary sclerosing cholangitis: sonographic findings. Abdom Imaging 1995; 20:109-112.
94. Silverman WB, Kaw M, Rabinovitz M, Schade RR, Bates BL: Complication rate of endoscop-ic retrograde cholangiopancreatography (ERCP) in patients with primary sclerosing cholangitis (PSC): is it safe? Gastroenterology 1994; 106:359.